Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study.
Nicolas WillietAngélique SaintAnne-Laure PointetDavid TougeronSimon PernotAstrid PozetDominique BechadeIsabelle TrouilloudNelson LourencoVincent HautefeuilleChristophe LocherJérome DesramePascal ArtruAnne Thirot BidaultBertrand Le RoyDenis PezetJean-Marc PhelipJulien TaiebPublished in: Therapeutic advances in gastroenterology (2019)
This study shows greater OS with FFX than with GN in patients with mPC. GN after FFX failure appears more feasible than the reverse sequence.
Keyphrases